Top

Published in:

01-05-2020 | Systemic Sclerosis | Review

Is biological therapy in systemic sclerosis the answer?

Authors: Durga Prasanna Misra, Sakir Ahmed, Vikas Agarwal

Published in: Rheumatology International | Issue 5/2020

Abstract

Systemic sclerosis is a systemic fibrosing disorder associated with significant morbidity and mortality, with no universally accepted disease-modifying therapy. Significant advances in the understanding of systemic sclerosis in recent years have guided the exploration of biological drugs in systemic sclerosis. In this narrative review, we summarize the published literature on biologic therapies in systemic sclerosis. A double-blind randomized trial, and an open label trial of tocilizumab (which antagonizes the interleukin 6 receptor), identified potential benefits in skin and lung fibrosis in systemic sclerosis; however, these differences failed to attain statistical significance. Two open-label trials compared rituximab (which depletes B lymphocytes) to conventional treatment/ cyclophosphamide in systemic sclerosis-associated interstitial lung disease (ILD), and revealed significant improvements in lung functions and skin disease with rituximab. Significant observational data also support the use of rituximab in skin, lung, muscle and joint manifestations of systemic sclerosis. Abatacept (which blocks T lymphocyte activation) has demonstrated utility for skin and joint disease in systemic sclerosis; a recent clinical trial failed to demonstrate benefits in improving skin thickness compared to placebo. Agents targeting type I interferons, interleukin 17 pathway, CD19 and plasma cells hold promise in systemic sclerosis; however, high-quality evidence is lacking. The results of different ongoing clinical trials targeting B lymphocytes, T lymphocytes, various cytokines (interleukins 6, 17, 4, 13, IL-1α), platelet-derived growth factor receptor, proteasome, integrins or oncostatin M may help guide future therapeutic regimens with biological agents in systemic sclerosis.

Available only for authorised users

Poudel DR, Jayakumar D, Danve A, Sehra ST, Derk CT (2018) Determinants of mortality in systemic sclerosis: a focused review. Rheumatol Int 38:1847–1858. https://doi.org/10.1007/s00296-017-3826-y CrossRefPubMed

Sánchez-Cano D, Ortego-Centeno N, Callejas JL et al (2018) Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Rheumatol Int 38:363–374. https://doi.org/10.1007/s00296-017-3916-x CrossRefPubMed

Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE (2015) Pathogenesis of systemic sclerosis. Front Immunol 6:272–272. https://doi.org/10.3389/fimmu.2015.00272 CrossRefPubMedPubMedCentral

Varga J, Trojanowska M, Kuwana M (2017) Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord 2:137–152. https://doi.org/10.5301/jsrd.5000249 CrossRef

Ahmed S, Misra DP, Agarwal V (2019) Interleukin-17 pathways in systemic sclerosis-associated fibrosis. Rheumatol Int 39:1135–1143. https://doi.org/10.1007/s00296-019-04317-5 CrossRefPubMed

Chakraborty D, Sumova B, Mallano T et al (2017) Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun 8:1130. https://doi.org/10.1038/s41467-017-01236-6 CrossRefPubMedPubMedCentral

Pedroza M, To S, Assassi S, Wu M, Tweardy D, Agarwal SK (2018) Role of STAT3 in skin fibrosis and transforming growth factor beta signalling. Rheumatology (Oxford) 57:1838–1850. https://doi.org/10.1093/rheumatology/kex347 CrossRef

Yan JF, Huang WJ, Zhao JF et al (2017) The platelet-derived growth factor receptor/STAT3 signaling pathway regulates the phenotypic transition of corpus cavernosum smooth muscle in rats. PLoS ONE 12:e0172191. https://doi.org/10.1371/journal.pone.0172191 CrossRefPubMedPubMedCentral

Chaturvedi S, Misra DP, Prasad N et al (2018) 5-HT2 and 5-HT2B antagonists attenuate pro-fibrotic phenotype in human adult dermal fibroblasts by blocking TGF-beta1 induced non-canonical signaling pathways including STAT3: implications for fibrotic diseases like scleroderma. Int J Rheum Dis 21:2128–2138. https://doi.org/10.1111/1756-185x.13386 CrossRefPubMed

10.

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417. https://doi.org/10.1007/s00296-011-1999-3 CrossRefPubMed

11.

Kitaba S, Murota H, Terao M et al (2012) Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 180:165–176. https://doi.org/10.1016/j.ajpath.2011.09.013 CrossRefPubMed

12.

Taniguchi T, Asano Y, Fukasawa T, Yoshizaki A, Sato S (2017) Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis. J Dermatol 44:967–971. https://doi.org/10.1111/1346-8138.13827 CrossRefPubMed

13.

Drobyski WR, Pasquini M, Kovatovic K et al (2011) Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant 17:1862–1868. https://doi.org/10.1016/j.bbmt.2011.07.001 CrossRefPubMedPubMedCentral

14.

Foeldvari I, Anton J, Friswell M et al (2017) Tocilizumab is a promising treatment option for therapy resistant juvenile localized scleroderma patients. J Scleroderma Relat Disord 2:203–207. https://doi.org/10.5301/jsrd.5000259 CrossRef

15.

Lythgoe H, Baildam E, Beresford MW, Cleary G, McCann LJ, Pain CE (2018) Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma. Rheumatology (Oxford) 57:398–401. https://doi.org/10.1093/rheumatology/kex382 CrossRef

16.

Khanna D, Denton CP, Jahreis A et al (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387:2630–2640. https://doi.org/10.1016/S0140-6736(16)00232-4 CrossRefPubMed

17.

Khanna D, Denton CP, Lin CJF et al (2018) Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 77:212–220. https://doi.org/10.1136/annrheumdis-2017-211682 CrossRefPubMed

18.

Arnold MB, Khanna D, Denton CP et al (2018) Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 57:152–157. https://doi.org/10.1093/rheumatology/kex396 CrossRef

19.

Denton CP, Ong VH, Xu S et al (2018) Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: Insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis 77:1362–1371. https://doi.org/10.1136/annrheumdis-2018-213031 CrossRefPubMedPubMedCentral

20.

Shima Y, Kawaguchi Y, Kuwana M (2019) Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy. Mod Rheumatol 29:134–139. https://doi.org/10.1080/14397595.2018.1452178 CrossRefPubMed

21.

Elhai M, Meunier M, Matucci-Cerinic M et al (2013) Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 72:1217–1220. https://doi.org/10.1136/annrheumdis-2012-202657 CrossRefPubMed

22.

Kono M, Yasuda S, Kono M, Atsumi T (2018) Tocilizumab reduced production of systemic sclerosis-related autoantibodies and anti-cyclic citrullinated protein antibodies in two patients with overlapping systemic sclerosis and rheumatoid arthritis. Scand J Rheumatol 47:248–250. https://doi.org/10.1080/03009742.2017.1297482 CrossRefPubMed

23.

Wakabayashi H, Kino H, Kondo M, Yamanaka K, Hasegawa M, Sudo A (2019) Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature. BMC Rheumatol 3:15. https://doi.org/10.1186/s41927-019-0063-x CrossRefPubMedPubMedCentral

24.

Das Neves MF, Oliveira S, Amaral MC, Alves JD (2015) Treatment of systemic sclerosis with tocilizumab. Rheumatology (Oxford) 54:371–372. https://doi.org/10.1093/rheumatology/keu435 CrossRef

25.

Zacay G, Levy Y (2018) Outcomes of patients with systemic sclerosis treated with tocilizumab: case series and review of the literature. Best Pract Res Clin Rheumatol 32:563–571. https://doi.org/10.1016/j.berh.2019.01.011 CrossRefPubMed

26.

Fernández-Codina A, Walker KM, Pope JE (2018) Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol 70:1820–1828. https://doi.org/10.1002/art.40560 CrossRefPubMed

27.

Khanna D, Lin CJF, Kuwana M, et al. (2018) Efficacy and safety of tocilizumab for the treatment of systemic sclerosis: results from a phase 3 randomized controlled trial [abstract]. Arthritis Rheumatol 70 (suppl 10).

28.

Murata KY, Sugie K, Takamure M, Ueno S (2002) Expression of the costimulatory molecule BB-1 and its receptors in patients with scleroderma-polymyositis overlap syndrome. J Neurol Sci 205:65–70. https://doi.org/10.1016/S0022-510X(02)00309-X CrossRefPubMed

29.

Takeuchi F, Kawasugi K, Nabeta H, Mori M, Tanimoto K (2002) Association of CTLA-4 with systemic sclerosis in Japanese patients. Clin Exp Rheumatol 20:823–828PubMed

30.

Ponsoye M, Frantz C, Ruzehaji N et al (2016) Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. Ann Rheum Dis 75:2142–2149. https://doi.org/10.1136/annrheumdis-2015-208213 CrossRefPubMed

31.

Cutolo M, Soldano S, Montagna P et al (2018) Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay. Arthritis Res Ther 20:157. https://doi.org/10.1186/s13075-018-1652-6 CrossRefPubMedPubMedCentral

32.

Khanna D, Spino C, Johnson S et al (2020) Abatacept in early diffuse cutaneous systemic sclerosis results of a phase 2 investigator-initiated, multicenter, double-blind randomized placebo-controlled trial. Arthritis Rheumatol 72:125–136. https://doi.org/10.1002/art.41055 CrossRefPubMed

33.

Chakravarty EF, Martyanov V, Fiorentino D et al (2015) Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis Res Ther 17:159. https://doi.org/10.1186/s13075-015-0669-3 CrossRefPubMedPubMedCentral

34.

Wehner Fage S, Arvesen KB, Olesen AB (2018) Abatacept improves skin-score and reduces lesions in patients with localized scleroderma: a case series. Acta Derm Venereol 98:465–466. https://doi.org/10.2340/00015555-2878 CrossRef

35.

Stausbøl-Grøn B, Olesen AB, Deleuran B, Deleuran MS (2011) Abatacept is a promising treatment for patients with disseminated morphea profunda: presentation of two cases. Acta Derm Venereol 91:686–688. https://doi.org/10.2340/00015555-1136 CrossRefPubMed

36.

De Paoli FV, Nielsen BD, Rasmussen F, Deleuran B, Søndergaard K (2014) Abatacept induces clinical improvement in patients with severe systemic sclerosis. Scand J Rheumatol 43:342–345. https://doi.org/10.3109/03009742.2013.812238 CrossRefPubMed

37.

Koca SS, Isik A, Ozercan IH, Ustundag B, Evren B, Metin K (2008) Effectiveness of etanercept in bleomycin-induced experimental scleroderma. Rheumatology (Oxford) 47:172–175. https://doi.org/10.1093/rheumatology/kem344 CrossRef

38.

Li T, Liu Y, Xu H (2017) Successful treatment of infliximab in a patient with scleroderma: a case report. Medicine (Baltimore). 96:e6737. https://doi.org/10.1097/MD.0000000000006737 CrossRef

39.

Ferguson ID, Weiser P, Torok KS (2015) A case report of successful treatment of recalcitrant childhood localized scleroderma with infliximab and leflunomide. Open Rheumatol 9:30–35. https://doi.org/10.2174/18743129014090100030 CrossRef

40.

Bargagli E, Galeazzi M, Bellisai F, Volterrani L, Rottoli P (2008) Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 75:346–349. https://doi.org/10.1159/000090248 CrossRefPubMed

41.

Diab M, Coloe JR, Magro C, Bechtel MA (2010) Treatment of recalcitrant generalized morphea with infliximab. Arch Dermatol 146:601–604. https://doi.org/10.1001/archdermatol.2010.120 CrossRefPubMed

42.

Antoniou KM, Mamoulaki M, Malagari K et al (2007) Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 25:23–28PubMed

43.

Lam GK, Hummers LK, Woods A, Wigley FM (2007) Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 34:1636–1637PubMed

44.

Tosounidou S, Macdonald H, Situnayake D (2014) Successful treatment of calcinosis with infliximab in a patient with systemic sclerosis/myositis overlap syndrome. Rheumatology (Oxford) 53:960–961. https://doi.org/10.1093/rheumatology/ket365 CrossRef

45.

Denton CP, Engelhart M, Tvede N et al (2009) An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 68:1433–1439. https://doi.org/10.1136/ard.2008.096123 CrossRefPubMed

46.

Ranganathan P (2005) Infliximab-induced scleredema in a patient with rheumatoid arthritis. J Clin Rheumatol 11:319–322. https://doi.org/10.1097/01.rhu.0000191162.66288.27 CrossRefPubMed

47.

Chimenti MS, Teoli M, Di Stefani A, Giunta A, Esposito M, Perricone R (2013) Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis. Eur J Dermatol 23:273–274. https://doi.org/10.1684/ejd.2013.1929 CrossRefPubMed

48.

Ramírez J, Hernández MV, Galve J, Canete JD, Sanmartí R (2012) Morphea associated with the use of adalimumab: a case report and review of the literature. Mod Rheumatol 22:602–604. https://doi.org/10.1007/s10165-011-0550-4 CrossRefPubMed

49.

Allanore Y, Devos-François G, Caramella C, Boumier P, Jounieaux V, Kahan A (2006) Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 65:834–835. https://doi.org/10.1136/ard.2005.044453 CrossRefPubMedPubMedCentral

50.

Distler JHW, Jordan S, Airò P et al (2011) Is there a role for TNF-α antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol 29:S40–S45PubMed

51.

Ichihara A, Jinnin M, Ihn H (2017) Treatment of psoriasis with ustekinumab improved skin tightening in systemic sclerosis. Clin Exp Rheumatol 35(Suppl 106):208–210PubMed

52.

Steuer AB, Peterson E, Lo Sicco K, Franks AG Jr (2019) Morphea in a patient undergoing treatment with ustekinumab. JAAD Case Rep 5:590–592. https://doi.org/10.1016/j.jdcr.2019.05.008 CrossRefPubMedPubMedCentral

53.

Ciechomska M, Skalska U (2018) Targeting interferons as a strategy for systemic sclerosis treatment. Immunol Lett 195:45–54. https://doi.org/10.1016/j.imlet.2017.10.011 CrossRefPubMed

54.

Goldberg A, Geppert T, Schiopu E et al (2014) Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther 16:R57. https://doi.org/10.1186/ar4492 CrossRefPubMedPubMedCentral

55.

Guo X, Higgs BW, Bay-Jensen AC et al (2015) Suppression of T cell activation and collagen accumulation by an anti-IFNAR1 mAb, anifrolumab, in adult patients with systemic sclerosis. J Invest Dermatol 135:2402–2409. https://doi.org/10.1038/jid.2015.188 CrossRefPubMed

56.

Bosello S, De Luca G, Tolusso B et al (2011) B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 10:624–630. https://doi.org/10.1016/j.autrev.2011.04.013 CrossRefPubMed

57.

Whitfield ML, Finlay DR, Murray JI et al (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 100:12319–12324. https://doi.org/10.1073/pnas.1635114100 CrossRefPubMedPubMedCentral

58.

Wollheim FA (2004) Is rituximab a potential new therapy in systemic sclerosis? new evidence indicates the presence of CD20-positive B-lymphocytes in scleroderma skin. J Clin Rheumatol 10:155. https://doi.org/10.1097/01.rhu.0000129090.86550.1e CrossRefPubMed

59.

Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E (2007) B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 56:3167–3168. https://doi.org/10.1002/art.22847 CrossRefPubMed

60.

Fineschi S, Reith W, Guerne PA, Dayer JM, Chizzolini C (2006) Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts. FASEB J 20:562–564. https://doi.org/10.1096/fj.05-4870fje CrossRefPubMed

61.

Lafyatis R, Kissin E, York M et al (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60:578–583. https://doi.org/10.1002/art.24249 CrossRefPubMedPubMedCentral

62.

Smith V, Van Praet JT, Vandooren B et al (2010) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 69:193–197. https://doi.org/10.1136/ard.2008.095463 CrossRefPubMed

63.

Bosello S, De Santis M, Lama G et al (2010) B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 12:R54. https://doi.org/10.1186/ar2965 CrossRefPubMedPubMedCentral

64.

Daoussis D, Liossis SNC, Tsamandas AC et al (2012) Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 30:S17–S22PubMed

65.

Smith V, Piette Y, Van Praet JT et al (2013) Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 40:52–57. https://doi.org/10.3899/jrheum.120778 CrossRefPubMed

66.

Ananieva LP, Desinova OV, Koneva OA et al (2013) Rituximab treatment for interstitial lung injury in scleroderma systematica. Naučno-Praktičeskaâ Revmatologiâ 51:514–523CrossRef

67.

Moazedi-Fuerst FC, Kielhauser SM, Brickmann K et al (2014) Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen. Scand J Rheumatol 43:257–258. https://doi.org/10.3109/03009742.2013.869617 CrossRefPubMedPubMedCentral

68.

Ananieva LP, Soloviyov SK, Beketova TV et al (2014) Anti-B-cell therapy at immune inflammatory rheumatic diseases: efficacy and tolerability in 229 patients. Naučno-Praktičeskaâ Revmatologiâ 52:495–506CrossRef

69.

Vilela VS, Maretti GB, Gama LMdS, Costa CHd, Rufino RL, Levy RA (2016) Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center. Rev Bras Reumatol Engl Ed 56:458–463. https://doi.org/10.1016/j.rbre.2016.06.003 CrossRefPubMed

70.

Sari A, Guven D, Armagan B et al (2017) Rituximab experience in patients with long-standing systemic sclerosis-associated interstitial lung disease: a series of 14 patients. J Clin Rheumatol 23:411–415. https://doi.org/10.1097/RHU.0000000000000584 CrossRefPubMed

71.

Mohammed AG, Alshihre A, Al-Homood I (2017) Rituximab treatment in patients with systemic sclerosis and interstitial lung disease. Ann Thorac Med 12:294–297. https://doi.org/10.4103/atm.ATM_30_17 CrossRefPubMedPubMedCentral

72.

Melsens K, Vandecasteele E, Deschepper E et al (2018) Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clin Belg 73:119–125. https://doi.org/10.1080/17843286.2017.1372244 CrossRefPubMed

73.

Koneva OA, Desinova OV, Ananyeva LP, Kovaleva NV (2018) The importance of high-resolution computed tomography in evaluating the efficacy of rituximab in patients with interstitial lung disease in systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya 56:591–599

74.

Fraticelli P, Fischetti C, Salaffi F et al (2018) Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. a single-centre case series study. Clin Exp Rheumatol 36:S142–S145

75.

Fabri M, Hunzelmann N, Krieg T, Rubbert A (2008) Discordant response to rituximab in a systemic sclerosis patient with associated myositis. J Am Acad Dermatol 58:S127–S128. https://doi.org/10.1016/j.jaad.2007.06.010 CrossRefPubMed

76.

McGonagle D, Tan AL, Madden J et al (2008) Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 47:552–553. https://doi.org/10.1093/rheumatology/kem357 CrossRef

77.

Daoussis D, Liossis SNC, Tsamandas AC et al (2010) Is there a role for B-cell depletion as therapy for scleroderma? a case report and review of the literature. Semin Arthritis Rheum 40:127–136. https://doi.org/10.1016/j.semarthrit.2009.09.003 CrossRefPubMed

78.

Haroon M, McLaughlin P, Henry M, Harney S (2011) Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. Ther Adv Respir Dis 5:299–304. https://doi.org/10.1177/1753465811407786 CrossRefPubMed

79.

Alexeeva EI, Valieva SI, Bzarova TM et al (2012) Experience of rituximab treatment in a patient with juvenile scleroderma. Nauchno-Prakticheskaya Revmatologiya 11:131–137

80.

Daoussis D, Antonopoulos I, Liossis SNC, Yiannopoulos G, Andonopoulos AP (2012) Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum 41:822–829. https://doi.org/10.1016/j.semarthrit.2011.11.007 CrossRefPubMed

81.

De Paula DR, Klem FB, Lorencetti PG, Muller C, Azevedo VF (2013) Rituximab-induced regression of CREST-related calcinosis. Clin Rheumatol 32:281–283. https://doi.org/10.1007/s10067-012-2124-z CrossRefPubMed

82.

Sumida H, Asano Y, Tamaki Z et al (2014) Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. J Dermatol 41:418–420. https://doi.org/10.1111/1346-8138.12461 CrossRefPubMed

83.

Akram Q, Roberts M, Oddis C, Herrick A, Chinoy H (2016) Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease. Reumatologia 54:35–37. https://doi.org/10.5114/reum.2016.58760 CrossRefPubMedPubMedCentral

84.

Ebata S, Yoshizaki A, Fukasawa T et al (2017) Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease. Scand J Rheumatol 46:247–252. https://doi.org/10.1080/03009742.2016.1231341 CrossRefPubMed

85.

Dall’Ara F, Lazzaroni MG, Antonioli CM, Airò P (2017) Systemic sclerosis with anti-RNA polymerase III positivity following silicone breast implant rupture: possible role of B-cell depletion and implant removal in the treatment. Rheumatol Int 37:847–851. https://doi.org/10.1007/s00296-017-3654-0 CrossRefPubMed

86.

Numajiri H, Yoshizaki A, Ebata S et al (2018) Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide. J Dermatol 45:e140–e141. https://doi.org/10.1111/1346-8138.14189 CrossRefPubMed

87.

Melissaropoulos K, Kraniotis P, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D (2019) Targeting very early systemic sclerosis: a case-based review. Rheumatol Int 39:1961–1970. https://doi.org/10.1007/s00296-019-04357-x CrossRefPubMed

88.

Jordan S, Distler JHW, Maurer B et al (2015) Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74:1188–1194. https://doi.org/10.1136/annrheumdis-2013-204522 CrossRefPubMed

89.

Daoussis D, Melissaropoulos K, Sakellaropoulos G et al (2017) A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 46:625–631. https://doi.org/10.1016/j.semarthrit.2016.10.003 CrossRefPubMed

90.

Thiebaut M, Launay D, Rivière S et al (2018) Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun Rev 17:582–587. https://doi.org/10.1016/j.autrev.2017.12.010 CrossRefPubMed

91.

Elhai M, Boubaya M, Distler O et al (2019) Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 78:979–987. https://doi.org/10.1136/annrheumdis-2018-214816 CrossRefPubMed

92.

Narváez J, Pirola JP, Lluch J, Juarez P, Nolla JM, Valenzuela A (2019) Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: a case series and systematic review of the literature. Autoimmun Rev 18:262–269. https://doi.org/10.1016/j.autrev.2018.10.006 CrossRefPubMed

93.

Daoussis D, Liossis SNC, Tsamandas AC et al (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49:271–280. https://doi.org/10.1093/rheumatology/kep093 CrossRef

94.

Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P (2018) Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford) 57:2106–2113. https://doi.org/10.1093/rheumatology/key213 CrossRef

95.

Vilela VS, Da Silva BRA, Da Costa CH, Lopes AJ, Levy RA, Rufino R (2018) Effects of treatment with rituximab on microcirculation in patients with long-term systemic sclerosis. BMC Res Notes 11:874. https://doi.org/10.1186/s13104-018-3994-1 CrossRefPubMedPubMedCentral

96.

Daoussis D, Tsamandas AC, Liossis SNC et al (2012) B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Res Ther 14:R145. https://doi.org/10.1186/ar3879 CrossRefPubMedPubMedCentral

97.

Daoussis D, Tsamandas A, Antonopoulos I et al (2016) B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis. Arthritis Res Ther 18:118 https://doi.org/10.1186/s13075-016-1017-y CrossRefPubMedPubMedCentral

98.

Antonopoulos I, Daoussis D, Lalioti ME et al (2019) B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis. Rheumatol Int 39:1889–1898. https://doi.org/10.1007/s00296-019-04350-4 CrossRefPubMed

99.

Schiopu E, Chatterjee S, Hsu V et al (2016) Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther 18:131. https://doi.org/10.1186/s13075-016-1021-2 CrossRefPubMedPubMedCentral

100.

Streicher K, Sridhar S, Kuziora M et al (2018) Baseline plasma cell gene signature predicts improvement in systemic sclerosis skin scores following treatment with inebilizumab (MEDI-551) and correlates with disease activity in systemic lupus erythematosus and chronic obstructive pulmonary disease. Arthritis Rheumatol 70:2087–2095. https://doi.org/10.1002/art.40656 CrossRefPubMed

101.

Fineschi S, Bongiovanni M, Donati Y et al (2008) In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis. Am J Respir Cell Mol Biol 39:458–465. https://doi.org/10.1165/rcmb.2007-0320OC CrossRefPubMed

102.

Goffin L, Seguin-Estevez Q, Alvarez M, Reith W, Chizzolini C (2010) Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts. Arthritis Res Ther 12:R73. https://doi.org/10.1186/ar2991 CrossRefPubMedPubMedCentral

103.

Gordon JK, Martyanov V, Franks JM et al (2018) Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis Rheumatol 70:308–316. https://doi.org/10.1002/art.40358 CrossRefPubMed

104.

Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg J-E, Mariette X (2007) Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 66:700–703. https://doi.org/10.1136/ard.2006.060772 CrossRefPubMed

105.

Denton CP, Merkel PA, Furst DE et al (2007) Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56:323–333. https://doi.org/10.1002/art.22289 CrossRefPubMed

106.

Rice LM, Padilla CM, McLaughlin SR et al (2015) Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 125:2795–2807. https://doi.org/10.1172/JCI77958 CrossRefPubMedPubMedCentral

107.

Isaacs JD, Hazleman BL, Chakravarty K, Grant JW, Hale G, Waldmann H (1996) Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. J Rheumatol 23:1103–1106PubMed

108.

Styczynski J, Tallamy B, Waxman I et al (2011) A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant 46:790–799. https://doi.org/10.1038/bmt.2010.209 CrossRefPubMed

109.

Spierings J, van Laar JM (2019) Is there a place for hematopoietic stem cell transplantation in rheumatology? Rheum Dis Clin North Am 45:399–416. https://doi.org/10.1016/j.rdc.2019.04.003 CrossRefPubMed

110.

Mantero JC, Kishore N, Ziemek J, et al. (2018) Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial. Clin Exp Rheumatol 36 Suppl 113:146–149.

111.

Beyer C, Schett G, Distler O, Distler JHW (2010) Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 62:2831–2844. https://doi.org/10.1002/art.27647 CrossRefPubMed

Title: Is biological therapy in systemic sclerosis the answer?
Authors: Durga Prasanna Misra
Sakir Ahmed
Vikas Agarwal
Publication date: 01-05-2020
Publisher: Springer Berlin Heidelberg
Keywords: Systemic Sclerosis
Tocilizumab
Abatacept
Rituximab
Scleroderma
Interferon
Rituximab
Published in: Rheumatology International / Issue 5/2020
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-020-04515-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2020

COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence

The evaluation of anxiety, depression and quality of life scores of children and adolescents with familial Mediterranean fever

Is vitamin D a panacea?

Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction

Tocilizumab-induced anaphylaxis in patients with adult-onset Still’s disease and systemic juvenile idiopathic arthritis: a case-based review

High interleukin-18 and low FOXP3 mRNAs in peripheral blood of women with severe systemic lupus erythematosus: a cross-sectional study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials